Impact of hemodialysis therapy on hepatitis C virus infection: A deeper insight

International Journal of Artificial Organs

Volumn 32, Issue 1, 2009, Pages 1-11

  Fabrizi, Fabrizio ^a,b   Messa, P ^a   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dialysis; HCV viremia; Hepatitis C virus; Natural history

Indexed keywords

DISEASE CONTROL; HEMODIALYZERS; PATIENT TREATMENT; VIRUSES;

ANTIVIRAL THERAPY; HAEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS VIREMIA; NATURAL HISTORY; VIRAL LOAD; VIRUS INFECTION;

DIALYSIS;

ALPHA INTERFERON; CUPROPHANE; CYTOKINE; ETHYLENE VINYL ALCOHOL COPOLYMER; INTERFERON; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; RIBAVIRIN; SCATTER FACTOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; APHERESIS; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DIALYSATE; DIALYSIS MEMBRANE; DISEASE COURSE; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; LIVER BIOPSY; MORTALITY; NONHUMAN; PLASMAPHERESIS; PREVALENCE; REVIEW; VIRUS LOAD; VIRUS PARTICLE;

EID: 64849110263     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903200101     Document Type: Review

References (62)

1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73 (Suppl 109): S1-99.
2. Finelli L, Miller JT, Tokars JI, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61.
3. Fissell RB, Bragg-Gresham JI, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOOPS. Kidney Int 2004; 65: 2335-42.
4. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P, and the HCV Collaborative Group. The changing epidemiology of hepatitis C virus infection in hemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19: 904-9.
5. Martin P, Fabrizi F. Hepatitis C and kidney disease. J Hepatol 2008; 49: 613-24.
6. Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in hemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14: 2056-9.
7. Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract 2004; 13: 129-35.
8. Hmajed F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol 2006; 78: 185-91.
9. Fabrizi F, Martin P, Dixit V, et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 1998; 80: 428-33.
10. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
11. Stehman-Breen C, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with HCV. Am J Kidney Dis 1998; 32: 629-34.
12. Di Napoli A, Pezzotti P, Di Lallo D, et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629-37.
13. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive hemodialysis patients: a population-based study. Nephrol Dial Transplant 2005; 20: 1662-9.
14. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14: 697-703.
15. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008; 15: 79-88.
16. Ishida H, Agishi T, Koyama I, et al. Hemodialysis paradox: survey on the incidence rate of hepatocellular carcinoma in antihepatitis C virus C-antibody positive chronic hemodialysis patients. Artif Organs 2001; 25: 58-60.
17. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol 2004; 10: 2209-12.
18. Gretch D, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22: 1-9.
19. Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886-9.
20. Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-8.
21. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
22. Ouzan D, Halfon P, Chanas M, et al. Relevance of hepatitis C virus detection, quantification, and genotypes in hemodialysis patients. Eur J Intern Med 1997; 8: 89-93.
23. Furusyo N, Hayashi J, Aruyama I, et al. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 2000; 95: 490-6.
24. Alric L, Di Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-9.
25. Gretch D, dela Rosa C, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies. Correlations and clinical implications. Ann Intern Med 1995; 123: 321-9.
26. Rampino T, Arbustini E, Gregorini M, et al. Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor. Kidney Int 1999; 56: 2286-91.
27. Azevedo HA, Villela-Noguiera C, Perez R, et al. Similar HCV viral load levels and genotype distribution among end-stage renal disease patients on hemodialysis and HCV-infected patients with normal renal function. J Nephrol 2007; 20: 609-16.
28. Cotler S, Diaz G, Gundlapalli S, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191-5.
29. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end-stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 3576-82.
30. Halfon P, Khiri H, Feryn JM, Sayada C, Chanas M, Ouzan D. Prospective virological follow-up of hepatitis C infection in a hemodialysis unit. J Viral Hepat 1998; 5: 115-21.
31. Fabrizi F, Martin P, Dixit V, et al. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 2000; 35: 122-9.
32. Akpolat I, Ozylkan E, Karagoz F, Akpolat T, Kandemir B. Hepatitis C in hemodialysis and nonuremic patients: a histopathological study. Int Urol Nephrol 1998; 30: 349-55.
33. Eleftheriadis T, Antoniadi G, Liakapoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20: 440-51.
34. Taniguchi M, Furukawa H, Shimamura T, et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C. Transplantation 2006; 81: 1747-9.
35. Yamashita T, Arai K, Sakai A, et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study. Hepatol Res 2006; 36: 167-75.
36. Schettler V, Monazahian M, Wieland E, et al. Reduction of hepatitis C virus load by HELP-LDL apheresis. Eur J Clin Invest 2001; 31: 154-5.
37. Schettler V, Monazahian M, Wieland E, Thomssen R, Muller GA. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma viral load. Ther Apher 2001; 5: 384-6.
38. Marson P, Boschetto R, De Silvestro G, et al. Changes in HCV viremia following LDL apheresis in a HCV positive patient with familiar hypercholesterolemia. Int J Artif Organs 1999; 22: 640-4.
39. Lindsay K, El-Shahawy M, Milstein S, et al. HCV RNA levels are lowered during hemodialysis in patients with chronic hepatitis C. Hepatology 1994; 20: 570A.
40. Okuda K, Hayashi H, Yokozeki K, Irie Y. Destruction of hepatitis C virus particles by hemodialysis. Lancet 1996; 347: 909-10.
41. Manzini P, Amore A, Brunetto MR, et al. Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? Nephron 1996; 72: 102-3.
42. Adorati M, Pipan C, Botta G. Membrane compatibility and clearance of hepatitis C virus in chronic dialysis patients. Nephron 1999; 82: 358.
43. Angelico M, Morosetti M, Passalacqua S, et al. Low levels of hepatitis C virus RNA in blood of infected patients under maintenance hemodialysis with high-biocompatibility, high-permeability filters. Digest Liver Dis 2000; 32: 724-8.
44. Noiri E, Nakao A, Oya A, Fujta T, Kimura S. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001; 37: 38-42.
45. Mizuno M, Higuchi T, Yanai M, Kanmatsuse K, Esumi M. Dialysis-membrane-dependent reduction and adsorption of circulating C virus during hemodialysis. Nephron 2002; 91: 235-42.
46. Badalamenti S, Catania A, Lunghi G, et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: Only coincidental phenomena? Am J Kidney Dis 2003; 42: 1-11.
47. Ishida H, Tanabe K, Tokumoto T, et al. Hepatitis C virus decreases in patients with maintenance hemofiltration therapy. Int J Artif Organs 2002; 28: 316-8.
48. Sampietro M, Graziani G, Badalamenti S, et al. Detection of hepatitis C virus in dialysate and in blood ultrafiltrate of HCV-positive patients. Nephron 1994; 68: 140.
49. Lombardi M, Cerrai T, Dattolo P, et al. Is the dialysis membrane a safe barrier against HCV infection ? Nephrol Dial Transplant 1995; 10: 578-9.
50. Valtuille R, Fernandez JL, Berridi J, et al. Evidence of hepatitis C virus passage across dialysis membrane. Nephron 1998; 80: 194-6.
51. Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreno A. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66: 470-3.
52. Hubmann R, Zazgornik J, Gabriel C, Garbeis B, Blauhut B. Hepatitis C virus- does it penetrate the hemodialysis membrane? PCR analysis of hemodialysis ultrafiltrate and whole blood. Nephrol Dial Transplant 1995; 10: 541-2.
53. Hayashi H, Okuda K, Yokosuka O, et al. Adsorption of hepatitis C virus particles onto the dialyzer membrane. Artif Organs 1997; 21: 1056-9.
54. Clark WR, Hamburger RJ, Lisaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 1999; 56: 2000-15.
55. Clark WR, Macias WL, Molitoris BA, Wang NH. Plasma protein adsorption to highly permeable hemodialysis membranes. Kidney Int 1995; 48: 481-8.
56. Angelini C, Badalamenti S, Lunghi G, et al. Evidence against hepatitis C virus trapping in dialysis membrane. Nephrol Dial Transplant 2002; 17: 317-8.
57. Malaponte G, Bevelacqua V, Fatuzzo P, et al. IL-1beta, TNF-α, and IL-6 release from monocytes in hemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 2002; 17: 1964-70.
58. Espinosa M, Arenas MD, Aumente MD, et al. Anemia associated with pegylated interferon-alpha2a and 2b therapy in hemodialysis patients. Clin Nephrol 2007; 67: 366-73.
59. Rampino T, Libetta C, De Simone W, et al. Hemodialysis stimulates hepatocyte growth factor release. Kidney Int 1998; 53: 1382-8.
60. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factors gene therapy of liver cirrhosis. Nat Med 1999; 5: 226-30.
61. Matsuda Y, Matsumoto K, Yamada A, et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/ cirrhosis. Hepatology 1997; 26: 81-9.
62. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA 1994; 91: 4357-61.